Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04209699 · ClinicalTrials.gov registry record · Phase 1
A Study Comparing the Effects of Famotidine Pretreatment and of Food on the Relative Bioavailability of BMS-986165 in Healthy Volunteers
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT04209699 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 18 participants.
The verdict
NCT04209699, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the effects of food and pH on the relative bioavailability (BA) of the tablet formulation of BMS-986165 in healthy volunteers
Interventions
- DRUG BMS-986165
- DRUG Famotidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2019-12-27 |
| Est. Completion | 2020-02-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04209699
The ClinicalTrials.gov registry entry for NCT04209699 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BMS-986165 is the first listed.
NCT04209699 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04209699 about?
NCT04209699 is a clinical study titled "A Study Comparing the Effects of Famotidine Pretreatment and of Food on the Relative Bioavailability of BMS-986165 in Healthy Volunteers". The primary purpose of this study is to evaluate the effects of food and pH on the relative bioavailability (BA) of the tablet formulation of BMS-986165 in healthy volunteers
What is the current status of trial NCT04209699?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2019-12-27. Estimated completion is 2020-02-11.
What interventions are being tested in trial NCT04209699?
The interventions under investigation include: BMS-986165 (DRUG), Famotidine (DRUG).
Who is sponsoring clinical trial NCT04209699?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.